^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JCAR020
i
Other names: JCAR020, MUC16 & IL-12 armored CAR T cell therapy, JCAR 020, ET-170, ET170 CAR, JCAR-020, ET 170, ET170
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS, Eureka Therap, Memorial Sloan-Kettering Cancer Center
Drug class:
IL-12 stimulant, MUC16-targeted CAR-T immunotherapy
Related drugs:
5ms
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
cyclophosphamide • fludarabine IV • JCAR020
over1year
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
MUC16 expression
|
cyclophosphamide • fludarabine IV • JCAR020
over2years
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
MUC16 expression
|
cyclophosphamide • fludarabine IV • JCAR020
almost4years
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 18 | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
MUC16 expression
|
fludarabine IV • JCAR020 • cyclophosphamide intravenous
over4years
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors (clinicaltrials.gov)
P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
Clinical • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
MUC16 expression
|
fludarabine IV • JCAR020 • cyclophosphamide intravenous
almost5years
A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC) (SGO 2020)
An additional cohort was treated at dose level 3 (3 × 106 CAR T cells/kg) following pretreatment with cyclophosphamide/fludarabine... IV and IP IL-12 secreting MUC16ecto-targeted CAR T cells were safely administered in the absence of chemotherapy. Toxicity was observed when the CAR T cells were given post-lymphodepleting chemotherapy. Dose escalation of CAR T cells will continue to dose level 5 (3 × 107 CAR T cells/kg).
Clinical • P1 data
|
EGFR (Epidermal growth factor receptor)
|
fludarabine IV • JCAR020 • cyclophosphamide intravenous
Share via
